Endocyte, Inc.  

(Public, NASDAQ:ECYT)   Watch this stock  
-0.11 (-4.95%)
After Hours: 2.11 0.00 (0.00%)
Feb 21, 4:41PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.05 - 2.22
52 week 1.98 - 4.33
Open 2.22
Vol / Avg. 0.00/187,142.00
Mkt cap 88.39M
P/E     -
Div/yield     -
EPS -1.01
Shares 42.27M
Beta 1.83
Inst. own 54%
Feb 28, 2017
Q4 2016 Endocyte Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -26792.00% -58956.79%
Operating margin -27507.38% -59961.34%
EBITD margin - -58694.61%
Return on average assets -22.43% -21.10%
Return on average equity -23.23% -21.93%
Employees 78 -
CDP Score - -


3000 Kent Ave Ste A1-100
United States - Map
+1-765-4637175 (Phone)
+1-765-4639271 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Officers and directors

John C. Aplin Ph.D. Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Michael A. Sherman President, Chief Executive Officer, Chief Financial Officer, Director
Age: 49
Bio & Compensation  - Reuters
Philip S. Low Ph.D. Chief Science Officer, Director
Age: 67
Bio & Compensation  - Reuters
Michael A. Brinkley Vice President - Quality
Age: 51
Bio & Compensation  - Reuters
Christopher P. Leamon Ph.D. Vice President - Research
Age: 49
Bio & Compensation  - Reuters
P. David Mozley M.D. Vice President - Imaging
Bio & Compensation  - Reuters
Katherine K. Parker Vice President of Human Resources
Age: 50
Bio & Compensation  - Reuters
Beth A. Taylor Corporate Controller
Age: 49
Bio & Compensation  - Reuters
Cooper Lesley R Russell Director
Age: 55
Bio & Compensation  - Reuters
Keith E. Brauer Independent Director
Age: 66
Bio & Compensation  - Reuters